Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPSNASDAQ:HSTONASDAQ:KRBPNASDAQ:MYMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPSCapstone Therapeutics$1.67-1.8%$1.88$1.58▼$16.18$260K-0.8325,756 shs8,074 shsHSTOHistogen$0.01-43.5%$0.02$0.05▼$0.55$43K1.1910,369 shs1,050 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsMYMDMyMD Pharmaceuticals$0.13+3.6%$0.17$1.75▼$63.90$308K2.15134,123 shs5.36 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPSCapstone Therapeutics0.00%-5.11%-7.22%-30.42%+166,999,900.00%HSTOHistogen-43.50%+2,400.00%-62.96%-64.29%-96.67%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-90.67%MYMDMyMD Pharmaceuticals+3.59%-6.81%-24.64%-63.89%-93.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPSCapstone TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPSCapstone Therapeutics 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/AKRBPKiromic BioPharma 0.00N/AN/AN/AMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPSCapstone Therapeutics$44.88M0.01N/AN/A($19.40) per share-0.09HSTOHistogen$19K2.25N/AN/A$3.13 per share0.00KRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPSCapstone Therapeutics-$2.56MN/A0.00∞N/AN/AN/AN/AN/AHSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/AKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/AMYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPSCapstone TherapeuticsN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPSCapstone Therapeutics0.281.140.47HSTOHistogenN/AN/AN/AKRBPKiromic BioPharmaN/A0.160.22MYMDMyMD PharmaceuticalsN/A0.620.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPSCapstone Therapeutics2.55%HSTOHistogenN/AKRBPKiromic BioPharma10.91%MYMDMyMD Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipCAPSCapstone Therapeutics42.80%HSTOHistogen3.30%KRBPKiromic BioPharma20.59%MYMDMyMD Pharmaceuticals2.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPSCapstone Therapeutics38160,00090,000N/AHSTOHistogen204.27 millionN/ANot OptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableHSTO, MYMD, KRBP, and CAPS HeadlinesRecent News About These CompaniesSarcopenia Market to Register Sustainable Growth at a CAGR of 8.1% During the Study Period (2020-2034) | DelveInsightJune 23, 2025 | prnewswire.co.ukPSarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightApril 24, 2025 | finance.yahoo.comMyMD-1 by TNF Pharmaceuticals for Hashimoto Thyroiditis: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPSarcopenia Market Anticipates Impressive Growth Trajectory Across 7MM During the Study Period (2020–2034) | DelveInsightSeptember 25, 2024 | finance.yahoo.comTNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related DeclineAugust 22, 2024 | finance.yahoo.comTNFA TNF Pharmaceuticals, Inc.August 16, 2024 | seekingalpha.comMyMD Pharmaceuticals is no more: Meet TNF PharmaceuticalsJuly 23, 2024 | fiercepharma.comFMyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.July 22, 2024 | businesswire.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024July 15, 2024 | investorplace.comMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical OfficerJune 17, 2024 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023May 17, 2024 | investorplace.comGold prices fall as rate jitters mount ahead of Fed meetingApril 30, 2024 | msn.comMorning Bid: Dollar bulls enter the China shopApril 17, 2024 | msn.comWhy Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?April 9, 2024 | investorplace.comRecursion Pharmaceuticals CEO sells over $1.16m in stockApril 7, 2024 | uk.investing.comExclusive-Software industry calls for more UK Government supportMarch 28, 2024 | msn.comMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingMarch 5, 2024 | finance.yahoo.comMyMD Pharmaceuticals Stock (NASDAQ:MYMD), Short Interest ReportFebruary 22, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSTO, MYMD, KRBP, and CAPS Company DescriptionsCapstone Therapeutics NASDAQ:CAPS$1.67 -0.03 (-1.76%) As of 06/27/2025 03:59 PM EasternCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.Histogen NASDAQ:HSTO$0.01 -0.01 (-43.50%) As of 06/27/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.Kiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.MyMD Pharmaceuticals NASDAQ:MYMD$0.13 +0.00 (+3.59%) As of 06/27/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
